KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $935000.0.

  • Xenon Pharmaceuticals' Other Accumulated Expenses fell 1342.59% to $935000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $935000.0, marking a year-over-year decrease of 1342.59%. This contributed to the annual value of $714000.0 for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Xenon Pharmaceuticals' Other Accumulated Expenses stood at $935000.0, which was down 1342.59% from $439000.0 recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Other Accumulated Expenses ranged from a high of $1.1 million in Q2 2024 and a low of $26000.0 during Q3 2021
  • Its 5-year average for Other Accumulated Expenses is $388444.4, with a median of $261000.0 in 2022.
  • Data for Xenon Pharmaceuticals' Other Accumulated Expenses shows a peak YoY increase of 110659.34% (in 2024) and a maximum YoY decrease of 8612.57% (in 2024) over the last 5 years.
  • Over the past 5 years, Xenon Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $118000.0 in 2021, then surged by 188.98% to $341000.0 in 2022, then crashed by 68.62% to $107000.0 in 2023, then surged by 567.29% to $714000.0 in 2024, then skyrocketed by 30.95% to $935000.0 in 2025.
  • Its last three reported values are $935000.0 in Q3 2025, $439000.0 for Q2 2025, and $450000.0 during Q1 2025.